Ask Warren

JONBUR Research · Update note

HLB · 028300 · Biotech & Pharma

HLB Outlines Group Mid-to-Long-Term Strategy After FDA Approval News; Financials Unchanged

Why this report

Written after:

HLB's group leadership presented a mid-to-long-term strategy at an IR event, and press reports quote management expecting a liver cancer drug decision within the year. This does not change the filed financials, which still show heavy losses, so our earlier cautious reading stands.

Written Oct 20, 2026 · Data as of Oct 19, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

On 2026-10-16, Etoday reported that HLB announced a group mid-to-long-term strategy after FDA approval of 'Rifitu'. We only have the headline, not the article text or any filing excerpt, so details are not available to us. Other headlines from 2026-10-15 say HLB unveiled the pipelines of five group companies and aims to join the global top 100 by 2030. They also say the co-heads expect an FDA decision on the liver cancer combination therapy within the year after resolving manufacturing issues, and that HLB is open to cooperating with big pharma on the US market. A Chosun Biz headline notes an eye drug has had five failed clinical trials, with US Phase 3 results expected in November. The share price closed at ₩42,950 on 2026-10-19, down from ₩44,400 on 2026-10-12, though it is up 44.9% over one month. No new numbers on revenue, costs or deal terms were given in the data. A conversion price adjustment was filed on 2026-10-15.

What it changes for the thesis

The previous report said the share price had risen sharply while filed results showed large losses, and that the data could not show how news would translate into revenue. That is still the case. The strategy announcement and the approval expectations are statements of intent. They are not yet visible in the statements: trailing revenue is ₩97.5B against an operating loss of ₩98.1B and a net loss of ₩213.5B. Cash is ₩26.4B against borrowings of ₩56.0B. Over the last 20 days, foreign investors were net sellers of about ₩152.9B and retail investors net buyers of about ₩161.6B. Foreign ownership is 13.0% versus 18.4% sixty days ago. These flow figures were not available in the earlier report, and they show a shift in who holds the shares, though not why.

What it changes for the valuation

The model has no fair value estimate for this company, and the previous report had none either, so there is no range to compare with the share price. On current data, price-to-book is 16.6 and price-to-sales is 58.7, with earnings multiples not meaningful because of losses. Among the peers listed, Samsung Biologics has a P/B of 7.9, Celltrion 2.6, Alteogen 31.0, Yuhan 2.7 and SK biopharmaceuticals 5.8. Market cap is about ₩5.7T. The news adds no figures that would let us estimate future earnings.

Closing view

The event adds a clearer statement of management ambitions and expectations for an FDA decision, but nothing that is quantified or confirmed in the filings. The financial position and valuation multiples are broadly as in the previous report, while foreign ownership has fallen and the price has eased slightly. The valuation still depends on outcomes not yet visible in the statements, such as regulatory decisions, clinical results in November and the funding of ongoing losses. This note offers no recommendation.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 20, 2026Update noteNewsHLB Outlines Group Mid-to-Long-Term Strategy After FDA Approval News; Financials Unchanged
  2. Oct 13, 2026InitiationHLB: Shares Up Sharply Over Three Months While Filed Results Still Show Large Losses

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information